Schumm samantha (18 Ergebnisse)

paperback. Zustand: Fine.

paperback. Zustand: Very Good. Cover and edges may have some wear.

Paperback. Zustand: Brand New. 270 pages. 6.93x0.79x9.92 inches. In Stock.

PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

paperback. Zustand: Fine.

PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Paperback. Zustand: Good. No Jacket. Pages can have notes/highlighting. Spine may show signs of wear. ~ ThriftBooks: Read More, Spend Less.

paperback. Zustand: Very Good.

PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Paperback. Zustand: Brand New. 244 pages. 6.10x0.60x9.10 inches. In Stock.

Zustand: New. 2025. paperback. . . . . . Books ship from the US and Ireland.

Paperback. Zustand: Brand New. 244 pages. 6.10x0.60x9.10 inches. In Stock.

Zustand: New.

Zustand: New. 2025. paperback. . . . . . Books ship from the US and Ireland.

Taschenbuch. Zustand: Neu. Neuware - In 2023, the National Academies convened an expert committee to assess the current use of racial and ethnic categories in biomedical research, review existing guidance for researchers, and provide new guidance for future use. The resulting 2024 report, Rethinking Race and Ethnicity in Biomedical Research, outlines nine actionable recommendations and associated resources for advancing the responsible use of race and ethnicity. The recommendations of Rethinking Race and Ethnicity in Biomedical Research address how to: decide whether to use race and ethnicity in different research contexts; characterize and disclose limitations of datasets that include racial and ethnic information; identify factors to investigate instead of or alongside race and ethnicity; include overlooked populations in analysis; and support sustained community engagement.…

Taschenbuch. Zustand: Neu. Neuware - The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options. To better understand these gaps, Gates Ventures and the Peterson Center on Healthcare asked the National Academies to examine current challenges and offer strategies and recommendations for improvement. The resulting report emphasizes that current research prioritization does not systematically account for disease burden and unmet needs, and describes how a robust, timely, accessible data system is needed. It also explores the ways in which implementing recommended policy changes could deliver better health outcomes. …

Zustand: NEW.